Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma

Table 4

Strong expression of PI3K/AKT/mTOR pathway proteins in HCC patients both in tumor and adjacent cirrhosis according to CLD etiology.

Etiology	PI3K		AKT				mTOR
	Tumor n (%)	Cirrhosis n (%)	value	Tumor n (%)	Cirrhosis n (%)	value	Tumor n (%)	Cirrhosis n (%)	value
Viral	14/39 (35.9)	3/27 (11.1)	0.048^b	16/41 (39.0)	14/35 (40.0)	1.000^b	10/41 (24.4)<	6/32 (18.8)	0.769^b
Nonviral	21/30 (53.8)	8/33 (24.2)	<0.001^b	15/39 (38.5)	15/29 (51.7)	0.399^b	6/39 (15.4)	4/32 (12.5)	1.000^b
value	0.111^a	0.315^b	—	0.959^a	0.348^a	—	0.314^a	0.491^a	—

Data are expressed as the absolute number/total of samples analyzed (percentage). HCC, hepatocellular carcinoma; CLD, chronic liver disease. ^aChi-square test. ^bFisher’s exact test.